China's investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of ...

For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be on the horizon ...

If at first you don’t succeed in gene therapy, then try, try again. | If at first you don’t succeed in gene therapy, then try ...

Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy pill, Novo ...

SK’s deal with India’s MSN Laboratories will allow the Korean company to extend its market exclusivity beyond October of 2032 ...

Eight months after more than doubling down on its construction of a $2 billion drug manufacturing facility in Holly Springs, ...

Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a ...

B. Braun Medical—a maker of IV solutions for hospitals, among other products—has initiated a recall in the United States and ...

Aurinia Pharmaceuticals has struck a patent infringement settlement with Teva Pharmaceuticals, which should help stave off ...

Less than a year after the FDA turned down the resubmitted application for the company’s leukemia prospect Dasynoc, Xspray ...

Boehringer Ingelheim has continued its rise up patient groups’ ranking of rare disease companies, adding to last year’s gains to cement its status toward the top of the leaderboards. | Boehringer ...

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no ...